Protecting the world against pertussis and other global emerging diseases
BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced many proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across all continents.
State-of-the-art manufacturing capabilities
BioNet commits to develop and manufacture innovative high-quality vaccines that comply with applicable regulatory requirements. BioNet aims to integrate quality beyond compliance in both products and processes through continuous improvement of our quality system.
Our vaccines are manufactured in accordance to Good Manufacturing Practices (GMP) PIC/S standards, and tested at each manufacturing step as per pharmacopeia requirements in our own quality control and testing facilities.
BioNet Key Facts
3
licensed
recombinant pertussis vaccines
200+
qualified and passionate individuals fueling vaccine innovation
25+
years’ experience
in vaccines
20
clinical trials
conducted
10+
mRNA
candidates
New Pertussis Vaccine Set for Implementation
BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine Against Pertussis
BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing
Lyon, France – October 29, 2025, BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, to produce its acellular pertussis vaccine.
BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN
Jakarta, May 28, 2025 — BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero), Indonesia’s state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to collaborate on the development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).
